GlassScriptPhysician profile
Malcolm M Roland
NPI 1033325022
$26,267.53
in general payments reported to CMS, 2019-2025
71 companies · $4,854 in 2025
The $4,854 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,249 · 2020: $2,523 · 2021: $3,575 · 2022: $4,252 · 2023: $4,097 · 2024: $4,718 · 2025: $4,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $81.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,587.77 |
| Education | $81.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,715.71 | 2021-2025 | Botox, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $1,821.15 | 2019-2025 | |
| Biogen, INC. | $1,203.15 | 2019-2025 | Vumerity, Tysabri, Aduhelm |
| Pfizer INC. | $1,161.62 | 2023-2025 | |
| Amgen INC. | $1,139.11 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $1,089.16 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Acadia Pharmaceuticals INC | $1,054.27 | 2019-2025 | Nuplazid |
| Jazz Pharmaceuticals INC. | $1,026.89 | 2019-2025 | |
| Ucb, INC. | $899.81 | 2020-2025 | Nayzilam, Briviact, Rystiggo |
| Emd Serono, INC. | $862.59 | 2019-2025 | Mavenclad |
| Sk Life Science, INC. | $826.72 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $790.97 | 2021-2025 | Ultomiris, Soliris |
| Harmony Biosciences LLC | $740.59 | 2020-2025 | Wakix |
| Neurocrine Biosciences, INC. | $718.92 | 2020-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $706.78 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Roland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.